Mithra and Searchlight Pharma Announce Filing of New Drug Submission for Estelle® in Canada

  • Searchlight Pharma’s New Drug Submission for a novel combined oral contraceptive (COC) accepted for review by Health Canada
  • Innovative product candidate developed by Mithra containing the unique native estrogen Estetrol (E4) and drospirenone (DRSP)
  • Potential commercialization in Canada under the trademark Nextstellis® expected in mid 2021

LIEGE (Belgium) and MONTREAL (Canada), 20 May 2020 – 7:30 CEST – Mithra and Searchlight Pharma announced today that Health Canada has accepted Searchlight Pharma’s New Drug Submission (“NDS”) for a novel combined oral contraceptive (COC) product.